Assembly Biosciences Inc (ASMB)vsEli Lilly and Company (LLY)
ASMB
Assembly Biosciences Inc
$26.95
+2.35%
HEALTHCARE · Cap: $442.93M
LLY
Eli Lilly and Company
$851.21
+9.80%
HEALTHCARE · Cap: $760.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 90047% more annual revenue ($65.18B vs $72.30M). LLY leads profitability with a 31.7% profit margin vs -8.5%. LLY earns a higher WallStSmart Score of 78/100 (B+).
ASMB
Hold44
out of 100
Grade: D
LLY
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+54.2%
Fair Value
$59.74
Current Price
$26.95
$32.79 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 46.6%
Revenue surging 477.3% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -5.1% — below average capital efficiency
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 28.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ASMB
The strongest argument for ASMB centers on Operating Margin, Revenue Growth, Debt/Equity. Revenue growth of 477.3% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : ASMB
The primary concerns for ASMB are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
ASMB profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
ASMB carries more volatility with a beta of 1.16 — expect wider price swings.
ASMB is growing revenue faster at 477.3% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 44/100), backed by strong 31.7% margins and 42.6% revenue growth. ASMB offers better value entry with a 54.2% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Assembly Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Assembly Biosciences, Inc. is a clinical-stage biotechnology company in the United States. The company is headquartered in South San Francisco, California.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?